MENLO PARK, CA, Nuvig Therapeutics, a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, announced the closing of a $161 million Series B financing. The financing was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities, and Norwest Venture Partners.
Read More